Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 436-442

  Baker, Aaron B ^a   Chatzizisis, Yiannis S ^b   Beigel, Roy ^b,c   Jonas, Michael ^b,c   Stone, Benjamin V ^c   Coskun, Ahmet U ^d   Maynard, Charles ^e   Rogers, Campbell ^f   Koskinas, Konstantinos C ^b   Feldman, Charles L ^b   Stone, Peter H ^b   Edelman, Elazer R ^b,c  

^a The University of Texas at Austin   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Northeastern University   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

Author keywords

Atherosclerosis; Endothelial shear stress; Heparanase; Thin cap fibroatheromas

Indexed keywords

ANGIOTENSIN II; CD45 ANTIGEN; GELATINASE; GELATINASE A; HEPARAN SULFATE; HEPARANASE; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; STREPTOZOCIN;

ANGIOCARDIOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMPUTATIONAL FLUID DYNAMICS; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME REGULATION; EXTRACELLULAR MATRIX; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INTRAVASCULAR ULTRASOUND; LIPID DIET; MACROPHAGE; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SHEAR STRESS; ZYMOGRAPHY;

ANIMALS; ANTIGENS, CD45; CORONARY ARTERY DISEASE; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HYPERLIPIDEMIAS; MALE; MATRIX METALLOPROTEINASE 2; PLAQUE, ATHEROSCLEROTIC; SWINE;

EID: 78649733041     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.003     Document Type: Article

References (38)

1. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 205:1262-1275.
2. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 478(Suppl.):C13-C18.
3. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 914:281-291.
4. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 1392:205-222.
5. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 155:551-561.
6. Wight T.N., Merrilees M.J. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004, 949:1158-1167.
7. Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med 2000, 102:60-65.
8. Sivaram P., Obunike J.C., Goldberg I.J. Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J Biol Chem 1995, 27050:29760-29765.
9. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 2655595:625-626.
10. Nugent M.A., Nugent H.M., Iozzo R.V., Sanchack K., Edelman E.R. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 2000, 9712:6722-6727.
11. Tran-Lundmark K., Tran P.K., Paulsson-Berne G., et al. Heparan sulfate in perlecan promotes mouse atherosclerosis. roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res 2008.
12. Vikramadithyan R.K., Kako Y., Chen G., et al. Atherosclerosis in perlecan heterozygous mice. J Lipid Res 2004, 4510:1806-1812.
13. Vlodavsky I., Goldshmidt O., Zcharia E., et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002, 122:121-129.
14. Gerrity R.G., Natarajan R., Nadler J.L., Kimsey T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001, 507:1654-1665.
15. Chatzizisis Y.S., Jonas M., Coskun A.U., et al. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation 2008, 1178:993-1002.
16. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006, 9812A:3Q-9Q.
17. Chatzizisis Y.S., Coskun A.U., Jonas M., et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007, 4925:2379-2393.
18. Cheng C., Tempel D., van Haperen R., et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006, 11323:2744-2753.
19. Gimbrone M.A., Topper J.N., Nagel T., Anderson K.R., Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000, 902230-902239. [discussion 9-40].
20. Stone P.H., Coskun A.U., Yeghiazarians Y., et al. Prediction of sites of coronary atherosclerosis progression: in vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior. Curr Opin Cardiol 2003, 186:458-470.
21. Bentzon J.F., Weile C., Sondergaard C.S., et al. Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2006, 2612:2696-2702.
22. Sukhova G.K., Wang B., Libby P., et al. C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 2005, 963:368-375.
23. Henney A.M., Wakeley P.R., Davies M.J., et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991, 8818:8154-8158.
24. Vine N., Powell J.T. Metalloproteinases in degenerative aortic disease. Clin Sci (Lond) 1991, 812:233-239.
25. Dollery C.M., Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006, 693:625-635.
26. Shi Z.S., Feng L., He X., et al. Vulnerable plaque in a Swine model of carotid atherosclerosis. AJNR Am J Neuroradiol 2009, 303:469-472.
27. Badimon L. Atherosclerosis and thrombosis: lessons from animal models. Thromb Haemost 2001, 861:356-365.
28. Cheruvu P.K., Finn A.V., Gardner C., et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol 2007, 5010:940-949.
29. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003, 10815:1772-1778.
30. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 10814:1664-1672.
31. Redgrave J.N., Gallagher P., Lovett J.K., Rothwell P.M. Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study. Stroke 2008, 396:1722-1729.
32. Cohen-Mazor M., Sela S., Mazor R., et al. Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients?. Am J Physiol Heart Circ Physiol 2008, 2942:H651-H658.
33. Chen G., Wang D., Vikramadithyan R., et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004, 4317:4971-4977.
34. Cain S.A., Baldock C., Gallagher J., et al. Fibrillin-1 interactions with heparin. J Biol Chem 2005, 28034:30526-30537.
35. Chatzizisis Y.S., Jonas M., Beigel R., et al. Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques. Atherosclerosis 2009, 2032:387-394.
36. Munesue S., Yoshitomi Y., Kusano Y., et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007, 28238:28164-28174.
37. Fitzgerald M., Hayward I.P., Thomas A.C., Campbell G.R., Campbell J.H. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis 1999, 1451:97-106.
38. van den Berg B.M., Spaan J.A., Vink H. Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch 2009, 4576:1199-1206.